Autres langues Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Temps Différé Japan Exchange Autres places de cotation 06:24:49 30/04/2024			Varia. 5j.	Varia. 1 janv.
7 337 ^JPY	+0,42 %		-0,05 %	+7,96 %

18/04	Shionogi & Co, Ltd. Annonce de nouvelles données issues de l'étude européenne PERSEUS (European Real-World Evidence Study) sur Fetroja®/F etcroja® (cefiderocol)	CI
29/03	Shionogi achève le rachat d'actions pour un montant de 75 milliards de yens	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024	25/04
Shionogi & Co., Ltd. - Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents	23/04
Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	19/04
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	19/04
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	19/04
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol)	18/04
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07/03
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06/03
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06/03
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	06/03
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05/03
GSK says ViiV's cabotegravir study supports longer HIV dose interval	05/03
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	05/03
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shionogi & Co., Ltd.

Actions

4507

JP3347200002

Autres langues

Filtres